

**Communicable Disease Epidemiology  
and Immunization Section**

401 5th Avenue, Suite 1250  
Seattle, WA 98104

206-296-4774 Fax 206-296-4803

TTY Relay: 711

www.kingcounty.gov/health

**Updated Health Advisory: Additional Resources Now Available for COVID-19 Pre-Exposure Prophylaxis from WA DOH Contractor Birds Eye Medical, 2 June 2022 (Updates highlighted in yellow below)**

(Original Health Advisory titled “Immunocompromised Patients and COVID-19: Pre-Exposure Prophylaxis, Testing, and Treatment Resources for King County Healthcare Providers, 13 April 2022”)

**Action Requested:**

- **Be aware of treatment options including monoclonal antibodies or MABs, as well as oral antivirals. Make a plan with your moderately or severely immunocompromised patients including where they can be promptly tested, evaluated for and access treatment in the event they become infected and are eligible.**
  - **This NIH page provides up-to-date treatment recommendations:** [Clinical Management | COVID-19 Treatment Guidelines \(nih.gov\)](#)
  - This WA DOH page also provides clinical information and guidance: [Therapeutics Information for Health Care Providers | Washington State /Department of Health](#)
  - This page details how providers and institutions can obtain access to MAb and oral antiviral therapeutics: [821-149-AllocationRequestProcessMonoclonalAntibodies.pdf \(wa.gov\)](#)
  - This page can guide you to organizations that currently have access to MAb and oral antiviral therapeutics: [COVID-19 Therapeutics Locator \(arcgis.com\)](#)
- **Be aware of pre-exposure prophylaxis resources and recommendations for moderately or severely immunocompromised patients**
  - Tixagevimab plus cilgavimab (Evusheld) is currently the only product authorized for PrEP
  - Further information can be found on the WA DOH therapeutics web page as well as through NIH and IDSA:
    - [Interim-DOH Guidance on Prioritization for Use of EVUSHELD \(wa.gov\);](#)
    - [Therapeutics Information for Health Care Providers | Washington State Department of Health;](#)
    - [Prevention of SARS-CoV-2 | COVID-19 Treatment Guidelines \(nih.gov\)](#)
    - [IDSA Guidelines on the Treatment and Management of Patients with COVID-19 \(idsociety.org\)](#)
  - The following page details how providers and institutions can obtain access to monoclonal antibody (MAb) and oral antiviral therapeutics (molnupiravir & ritonavir-boosted nirmatrelvir [Paxlovid]) and Tixagevimab plus cilgavimab (Evusheld) PrEP [821-149-AllocationRequestProcessMonoclonalAntibodies.pdf \(wa.gov\)](#)
  - This page can guide you to organizations that currently have access to MAb, including Tixagevimab plus cilgavimab (Evusheld), and oral antiviral therapeutics nationally and locally: [COVID-19 Therapeutics Locator \(arcgis.com\)](#)

**Communicable Disease Epidemiology  
and Immunization Section**

401 5th Avenue, Suite 1250  
Seattle, WA 98104

206-296-4774 Fax 206-296-4803

TTY Relay: 711

www.kingcounty.gov/health

- **UPDATE: If your organization does not have the capacity to administer Evusheld, providers can submit referral orders to [Birds Eye Medical](#). This company is contracted by WA DOH for provision of testing and treatment for COVID-19, by faxing a copy of this [form](#) to (360) 878-8330.**
  - **Birds Eye Medical will also accept referrals in any format if more convenient as long as they contain the following information:**
    - Patient Last name
    - Patient First name
    - DOB
    - Sex at birth
    - Contact Phone
    - Address(preferred)
    - Indication for Evusheld
    - Provider Order, including dosage
    - Provider NPI#
- **You can also refer patients to the [Birds Eye Medical Website](#) or to call (360) 688-7044 where they can schedule a EVUSHELD appointment after you provide a referral.**
- **Birds Eye Medical has multiple clinic locations within King County currently operating. Once they receive a referral, they will contact patients directly to schedule them at a clinic and time that works best with their schedule.**
- **Be aware that post-exposure prophylaxis is not currently recommended as all products authorized for this use are not effective against the predominant Omicron variant**
- **Be aware of testing locations and resources in King County**
  - Prompt testing after exposure or development of symptoms is important to ensure eligibility for available treatments.
  - [COVID-19 testing locations and guidance - King County](#)
  - [Increasing Community Access to Testing \(ICATT\) for COVID-19 \(cdc.gov\)](#)
  - There are also State and Federal programs for individuals to order home based over-the-counter antigen tests for free so they can have them on hand after exposures or new symptoms arise:
    - Federal - [COVIDtests.gov](#)
    - State - [Say Yes! COVID TEST](#)
- **Be aware of locations within King County that can provide testing and rapid treatment with oral antiviral medications through the federal [Test to Treat Program](#)**
  - This page can help you and patients locate participating Test To Treat locations: [COVID-19 Test to Treat Locator English \(arcgis.com\)](#)

**Communicable Disease Epidemiology  
and Immunization Section**

401 5th Avenue, Suite 1250  
Seattle, WA 98104

**206-296-4774** Fax 206-296-4803

TTY Relay: 711

[www.kingcounty.gov/health](http://www.kingcounty.gov/health)

**Background:**

[Moderately or severely Immunocompromised](#) patients are at increased risk for severe disease, hospitalization, and death from COVID-19. [Many conditions and treatments](#) can cause a person to be immunocompromised including immunosuppressive medications for cancer or autoimmune disease, solid organ or bone marrow transplants, and infections like HIV. It is very important for immunocompromised patients to continue to use layered COVID-19 prevention measures including staying up to date with [vaccinations](#) (including extra dose of primary series and boosters when eligible), [pre-exposure prophylaxis \(PrEP\)](#), [masking](#) with high-quality masks (e.g., N95, KN95, KF94), avoiding crowded indoor settings, social distancing, and [testing](#) when appropriate after exposure or when symptomatic.

Given that moderately or severely immunocompromised patients have increased risk for severe disease, hospitalization, and death with COVID-19 infection, even when up to date with vaccination recommendations, it is important for healthcare providers to be aware of resources for vaccination, PrEP, testing, and treatment so these patients can rapidly access these lifesaving interventions.